戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osate, glucuronate, ibuprofen, naproxen, and ketoprofen).
2 5700 days for carbamazepine to <1-2 days for ketoprofen.
3 inflammatory drugs: ibuprofen, naproxen, and ketoprofen.
4 profen, oxaprozin, fenoprofen, naproxen, and ketoprofen.
5 er blockade by the COX-1-selective inhibitor ketoprofen.
6 non-selective NSAIDs, such as Diclofenac and Ketoprofen.
7 ent cardiotoxicity of Diclofenac compared to Ketoprofen.
8                                              Ketoprofen (1-75 mg orally) blocked uptake in these orga
9 s significantly reduced by pretreatment with ketoprofen (3.56 +/- 0.81 and 1.30 +/- 0.18 percentage i
10 s significantly reduced by pretreatment with ketoprofen (3.56 0.81 and 1.30 0.18 percentage injected
11 after IH-1 by systemic NSAID administration (ketoprofen; 55 +/- 9%; p < 0.001) or spinal p38 MAP kina
12 e and about 2 h after oral administration of ketoprofen (75 mg).
13 s been applied to the rapid synthesis of (S)-ketoprofen, a commercially successful oral and topical a
14 ed, whereas the recoveries for acidic drugs (ketoprofen and ibuprofen) were in the range of 76%-86%.
15    Pain-related acid effects were blocked by ketoprofen and morphine but not by norBNI.
16 D tablets of aspirin, ibuprofen, diclofenac, ketoprofen and naproxen have been touched.
17                   The desired separation for ketoprofen and papaverine was established based on a sin
18 artificial analytes and experimental data of ketoprofen and papaverine were used to test the proposed
19 sics (the nonsteroidal antiinflammatory drug ketoprofen and the mu-opioid agonist morphine) or by the
20 ry drugs) naproxen, ibuprofen, flurbiprofen, ketoprofen, and fenoprofen.
21 tion group (acetylsalicylic acid, ibuprofen, ketoprofen, and tiaprofenic acid), every 30 minutes: 20%
22 93 effects were blocked by norBNI but not by ketoprofen, and were only attenuated by morphine.
23 immortalized human cardiomyocytes exposed to Ketoprofen are subjected to tolerable stress events, con
24 clonidine, and lidocaine), nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine), o
25 roimidazolone formation at Arg-410 inhibited ketoprofen binding and esterase activity; correspondingl
26                                              Ketoprofen blocked approximately 84% of the binding site
27               We also compare the binding of ketoprofen by equine SA to binding of it by bovine and l
28 ution of CYP450 in further transformation of ketoprofen byproducts is also reported.
29     Five organic acids (sulindac, ibuprofen, ketoprofen, diclofenac, and norfloxacin) were infused in
30 bumin complexed with four NSAIDs (ibuprofen, ketoprofen, etodolac, and nabumetone) and the active met
31 in all organs of the body, demonstrated that ketoprofen had unexpectedly high potency, that celecoxib
32 nically used NSAIDs (indomethacin, sulindac, ketoprofen, ibuprofen, diclofenac, ketorolac, etc., cycl
33 esent study aimed to evaluate the effects of Ketoprofen in comparison with Diclofenac in immortalized
34 orrespondingly, glycation in the presence of ketoprofen inhibited Arg-410 modification and loss of es
35                                              Ketoprofen is a highly potent and selective COX-1 inhibi
36 r risk profile for Diclofenac as compared to Ketoprofen is reported, the mechanisms through which NSA
37 nti-inflammatory drugs, spantide II (SP) and ketoprofen (KP) on the skin permeation.
38                         Spantide II (SP) and ketoprofen (KP) were used as model drugs for combined de
39 ntitation of the (R)- and (S)-enantiomers of ketoprofen (kt), a potent nonsteroidal, anti-inflammator
40 he pharmacokinetics and safety of the NSAID, ketoprofen (KTP), in gel formulations.
41 , on the size and stability of the colloidal ketoprofen (KTP)-rich phase generated by liquid-liquid p
42 IDs are Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Loxoprofen, Nabumetone, Naproxen, Nimesulide
43 and binding in the spleen (in vivo IC (50)), ketoprofen (&lt;0.24 muM) was more than 10-fold more potent
44 y volunteers, followed by blocked scans with ketoprofen (n = 8), celecoxib (n = 8), or aspirin (n = 8
45 > R) unidirectional inversion [flurbiprofen, ketoprofen, naproxen, and 2-(4-tert-butylphenyl)propioni
46 tion recoveries for the mu-EME of ibuprofen, ketoprofen, naproxen, and diclofenac exceed 40% in real
47 ic acid, diclofenac, gemfibrozil, ibuprofen, ketoprofen, naproxen, sulfamethoxazole, and sildenafil).
48 azepine, diclofenac, gemfibrozil, ibuprofen, ketoprofen, norethindrone, propranolol, and warfarin) wi
49 zation of intracellular transformation using ketoprofen showed that CYP450 is not the sole intracellu
50 with either orally or topically administered ketoprofen were generated using both pcSFC and LC as the